Drug intelligence / Profile preview

VacV00X

Development stage: Unknown
Lead developer: VacV Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

VacV00X is an investigational oncolytic virus therapy developed by VacV Biotheraputics (UK) Ltd. As an oncolytic virus, it is designed to selectively infect and destroy cancer cells while sparing normal tissues. The mechanism of action typically involves viral replication within tumor cells, leading to cell lysis and the release of tumor antigens that can stimulate an anti-tumor immune response. Specific details regarding its molecular target(s), cancer indications, or clinical trial results are not publicly available as of March 2025[1][2].

Beyond the preview

Go deeper on VacV00X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VacV00X.

Explore the full profile